Do Self-adhesive Resin Composites Release More Monomers? A Comparative High-performance Liquid Chromatographic Analysis.

PURPOSE: To comparatively evaluate the elution of residual monomers (bis-GMA, bis-EMA, TEG-DMA, and HEMA) from two self-adhesive flowable resin composites, a giomer, and a nano-flowable resin composite over five different time intervals, using high-performance liquid chromatography (HPLC). MATERIALS AND METHODS: Four flowable resin composites were investigated (Vertise Flow, Constic, Beautifil Flow Plus F03, and Filtek Z350 XT). Immediately after polymerization, each sample was immersed in 75% ethanol/water solution and stored in amber-colored bottles at room temperature. HPLC analysis was performed at predefined time intervals: 1 h, 24 h, 4 days, 8 days and 16 days. The extraction solution was changed after each analysis. Data were analyzed with repeated-measures ANOVA and one-way ANOVA with Tukey's post-hoc test at p < 0.05. RESULTS: The highest mean concentration of residual monomers was eluted from Beautifil, followed by Filtek, and both were significantly higher (p < 0.05) than the mean concentration of eluates from self-adhesive resin composites (Vertise Flow and Constic). Vertise Flow released significantly higher concentrations of HEMA than all the other tested materials. At 1 h post-immersion, 52.2% of monomers were eluted, and continued to elute at a reduced rate throughout the study duration. TEG-DMA was the fastest monomer to leach out, while bis-GMA exhibited significantly higher total mean concentration. The elution rate was significantly dependent on the molecular weight of the eluted monomers. CONCLUSION: No specific elution behavior can be attributed to self-adhesive RBCs. Elution of residual monomers is dependent on each material's composition, resin matrix characteristics, and the monomer's molecular weight.

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder.

Major depressive disorder (MMD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD fail to achieve response or remission leading to treatment-resistant depression (TRD). One of the psychopharmacological strategies to overcome TRD is using a combination of an antipsychotic as an augmenting agent with selective serotonin reuptake inhibitors (SSRIs). Among which, an atypical antipsychotic, quetiapine (QUE), and an SSRI, escitalopram (ESC), were formulated as a fixed-dose combination as a fast-dissolving film by coaxial electrospinning. The resultant fiber's morphology was studied. SEM images showed that the drug-loaded fibers were smooth, un-beaded, and non-porous with a fiber diameter of 0.9 ± 0.1 µm, while the TEM images illustrated the distinctive layers of the core and shell, confirming the successful preparation of these fibers. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies confirmed that both drugs were amorphously distributed within the drug-loaded fibers. The drug-loaded fibers exhibited a disintegration time of 2 s, which accelerated the release of both drugs (50% after 5 min) making it an attractive formulation for oral mucosal delivery. The ex vivo permeability study demonstrated that QUE was permeated through the buccal membrane, but not ESC that might be hindered by the buccal epithelium and the intercellular lipids. Overall, the developed coaxial fibers could be a potential buccal dosage form that could be attributed to higher acceptability and adherence among vulnerable patients, particularly mentally ill patients.